New Research Published in the Journal of Diabetes Science and Technology Demonstrates the Ability of Spatial Frequency Domain Imaging (SFDI) to Stratify Severity of Microvascular Disease.

Irvine, CA—February 6, 2023—

February 6, 2023

A new peer-reviewed article about Modulim’s technology was recently published in the Journal of Diabetes Science and Technology. The article, entitled “Stratification of Microvascular Disease Severity in the Foot using Spatial Frequency Domain Imaging (SFDI),” was a collaboration between researchers at the University of Arizona and Modulim.

The research revealed that decreased microvascular perfusion (HbT1) and decreased oxygen extraction (StO2) in the foot correlated with the clinical severity of microvascular disease. Clinical stratification of microvascular disease was successfully determined based on the clinical diagnosis of diabetes, neuropathy, and retinopathy. The study data demonstrated that SFDI biomarkers in the foot show significant differences between four different microvascular disease risk-stratified groups. In contrast, neither the ankle-brachial index (ABI), nor the toe brachial index (TBI), were able to do the same.

Microvascular disease has been shown to correlate with amputation risk and wound healing capability1. Thus, in order to improve outcomes, healthcare teams need better methods to determine the level of microvascular disease in the foot to help guide care plans.

Link to publication here:

About Modulim

Modulim delivers transformative health technology solutions that empower clinicians across the continuum of care to improve patient outcomes. Clarifi®, powered by Spatial Frequency Domain Imaging (SFDI) technology, quantifies and maps tissue health at the point-of-care through non-contact rapid microvascular assessment. Modulim Cloud™ promotes timely, proactive data-driven decisions to reduce lower-limb complications by digitally connecting clinicians and healthcare systems. Modulim is based in Irvine, CA, with a team dedicated to delivering powerful healthcare solutions that elevate the standard of care for patients with diabetes, kidney disease, and peripheral vascular disease.

Clarifi is a registered trademark of Modulated Imaging (dba Modulim).



  1. Behroozian, Adam, and Joshua A. Beckman. “Microvascular disease increases amputation in patients with peripheral artery disease.” Arteriosclerosis, thrombosis, and vascular biology40.3 (2020): 534-540.



Blake Byrne